EUVIMEDEUVIMED entdecken
Open Access

Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy

Shannon N Geels, Alexander Moshensky, Rachel S Sousa, Claire Murat, Matias A Bustos, Benjamin L Walker, Rima Singh, Stacey N Harbour, Giselle Gutierrez, Michael Hwang, Thorsten R Mempel, Casey T Weaver und 5 weitere

Cancer Cell · 2024-06 · 42 (6) · 1051-1066.e7

DOI: 10.1016/j.ccell.2024.05.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-06. Verfasst von Shannon N Geels und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Physiology and Biophysics, University of California, Irvin…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Programmed Cell Death 1 Receptor, Melanoma. Die Arbeit wurde bisher 125-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PD-1 blockade unleashes potent antitumor activity in CD8+ T cells but can also promote immunosuppressive T regulatory (Treg) cells, which may worsen the response to immunotherapy. Tumor-Treg inhibition is a promising strategy to improve the efficacy of checkpoint blockade immunotherapy; however, our understanding of the mechanisms supporting tumor-Tregs during PD-1 immunotherapy is incomplete. Here, we show that PD-1 blockade increases tumor-Tregs in mouse models of melanoma and metastatic melanoma patients. Mechanistically, Treg accumulation is not caused by Treg-intrinsic inhibition of PD-1 signaling but depends on an indirect effect of activated CD8+ T cells. CD8+ T cells produce IL-2 and colocalize with Tregs in mouse and human melanomas. IL-2 upregulates the anti-apoptotic protein ICOS on tumor-Tregs, promoting their accumulation. Inhibition of ICOS signaling before PD-1 immunotherapy improves control over immunogenic melanoma. Thus, interrupting the intratumor CD8+ T cell:Treg crosstalk represents a strategy to enhance the therapeutic efficacy of PD-1 immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesT-Lymphocytes, RegulatoryProgrammed Cell Death 1 ReceptorMelanomaInducible T-Cell Co-Stimulator ProteinImmunotherapyImmune Checkpoint InhibitorsInterleukin-2AnimalsHumansMiceMice, Inbred C57BLSignal TransductionMelanoma, ExperimentalCell Line, Tumor

Stichwörter der Autor:innen

CD8(+) T cellsF-IVMICOSIL-2PD-1T regulatory cellsTregfunctional intravital microscopymelanomatumor tolerance

Substanzen

Programmed Cell Death 1 ReceptorInducible T-Cell Co-Stimulator ProteinImmune Checkpoint InhibitorsInterleukin-2PDCD1 protein, humanICOS protein, human

Autor:innen und Institutionen

  • Institute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
  • Institute for Immunology, University of California, Irvine, Irvine, CA, USA; Center for Complex Biological Systems, University of California, Irvine, Irvine, CA, USA; NSF-Simons Center for Multiscale Cell Fate Research,…
  • Department of Translational Molecular Medicine, Saint John's Cancer Institute, Santa Monica, CA, USA.
  • Center for Complex Biological Systems, University of California, Irvine, Irvine, CA, USA; NSF-Simons Center for Multiscale Cell Fate Research, University of California, Irvine, Irvine, CA, USA.
  • Institute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Biological Chemistry, University of California, Irvine, Irvine, CA, USA.
  • Department of Pathology, University of Alabama, Birmingham, Birmingham, AL, USA.

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • NIAMS NIH HHS
  • NINDS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Science Foundation
  • Melanoma Research Alliance
  • Heising-Simons Foundation

Zitieren

APA

Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., Mempel, T. R., Weaver, C. T., Nie, Q., Hoon, D. S. B., Ganesan, A. K., Othy, S., & Marangoni, F. (2024). Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell, 42(6), 1051-1066.e7. https://doi.org/10.1016/j.ccell.2024.05.013

Vancouver

Geels SN, Moshensky A, Sousa RS, Murat C, Bustos MA, Walker BL, et al. Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy. Cancer Cell. 2024;42(6):1051-1066.e7. doi:10.1016/j.ccell.2024.05.013

BibTeX
@article{Geels2024,
  author = {Geels, Shannon N and Moshensky, Alexander and Sousa, Rachel S and Murat, Claire and Bustos, Matias A and Walker, Benjamin L and Singh, Rima and Harbour, Stacey N and Gutierrez, Giselle and Hwang, Michael and Mempel, Thorsten R and Weaver, Casey T and Nie, Qing and Hoon, Dave S B and Ganesan, Anand K and Othy, Shivashankar and Marangoni, Francesco},
  title = {Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {6},
  pages = {1051--1066.e7},
  doi = {10.1016/j.ccell.2024.05.013}
}
Kostenlos starten →